» Articles » PMID: 32416453

Prevention of Acute Graft-versus-host-disease by Withaferin a Via Suppression of AKT/mTOR Pathway

Overview
Date 2020 May 17
PMID 32416453
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Acute Graft versus Host Disease (aGVHD) is a frequent and serious complication in patients receiving allogeneic bone marrow transplantation (allo-BMT) and often requires rigorous prophylaxis. The current treatment regimens for aGVHD are associated with several side effects which necessitates the development of novel interventions that prevent aGVHD without precluding graft-versus-tumor effects. In the present study, we show that treatment of donor graft with plant steroidal lactone Withaferin A (WA) prior to transplantation markedly reduced aGVHD mediated damage in target organs without compromising the graft-versus.-tumor activity of the transplanted lymphocytes. WA abrogated post-transplant cytokine storm associated with allo-activation of donor lymphocytes. This was attributed to the ability of WA to inhibit early signaling events in T-cell activation including lymphoblast formation and activation of AKT/mTOR pathway. Mortality and morbidity related to allo-transplantation was significantly reduced in recipients of WA treated donor splenocytes compared to recipient of vehicle treated donor splenocytes. Further, WA treatment did not have any effect on reconstitution of lymphoid and myeloid lineages in recipients, resulting in stable and complete donor chimerism. In agreement with previous reports showing the effectiveness of WA in a mouse model of partial chimerism, our data further establishes that WA is able to attenuate aGVHD in an MHC-mismatched high dose chemo-conditioned murine model without compromising engraftment. This study provides compelling scientific basis for possible application of WA for prevention and treatment of aGVHD in patients receiving allo-BMT.

Citing Articles

Extract Mitigates Experimental Acute Graft versus Host Disease Without Abrogating Graft Versus Leukemia Effect.

Gupta S, Gohil D, Momin M, Yadav S, Chichra A, Punatar S Cell Transplant. 2024; 33:9636897241226573.

PMID: 38258793 PMC: 10807391. DOI: 10.1177/09636897241226573.


Safety, toxicity and pharmacokinetic assessment of oral Withaferin-A in mice.

Gupta S, Jadhav S, Gohil D, Panigrahi G, Kaushal R, Gandhi K Toxicol Rep. 2022; 9:1204-1212.

PMID: 36518386 PMC: 9742883. DOI: 10.1016/j.toxrep.2022.05.012.


Baicalin regulates autophagy to interfere with small intestinal acute graft-versus-host disease.

Sun X, Pisano M, Xu L, Sun F, Xu J, Zheng W Sci Rep. 2022; 12(1):6551.

PMID: 35449393 PMC: 9023573. DOI: 10.1038/s41598-022-10564-7.


Tackling Chronic Inflammation with Withanolide Phytochemicals-A Withaferin a Perspective.

Logie E, Vanden Berghe W Antioxidants (Basel). 2020; 9(11).

PMID: 33182809 PMC: 7696210. DOI: 10.3390/antiox9111107.